Developer docs
API playgroundTry for free, no card

Search company profiles

Juvenescence

Full company profile

uuid00009b7

Namestring
Juvenescence
Legal namestring
Juvenescence Limited
Websiteurl
juvlabs.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Juvenescence is a clinical-stage AI-enabled biotechnology company developing medicines that target core mechanisms of aging to treat and prevent age-related diseases rather than individual disease symptoms. Its pipeline spans five core therapeutic candidates: a PAI-1 inhibitor (MDI-2517) advancing to Phase 2 in chronic kidney disease and fibrotic lung disease, a CD38 inhibitor (NTX-748) targeting NAD metabolism and cognitive aging, a GDF-15 monoclonal antibody for cardio-metabolic conditions, plus Ketone Rx and Plasmalogen candidates. Underpinning the pipeline is the proprietary JuvAI platform, which combines JuvAI Biology (an LLM-enabled biomedical knowledge graph with 85 million nodes and 400 million relationships), JuvAI Chemistry (point-cloud ML and a 3D variational GAN for molecular design), and JuvAI Clinic (adaptive clinical trial optimization). Nine granted patents protect core platform components.

The company operates a dual model combining internal pipeline development with a strategic portfolio of minority investments in adjacent platform companies, including Relation Therapeutics ($1.7B Novartis collaboration), LyGenesis (Phase 2a liver cell therapy), Morphoceuticals, Chrysea (Sprevive spermidine supplement), MDI Therapeutics, Serina Therapeutics, Napa Therapeutics (joint venture with Buck Institute and Insilico Medicine), and others. Juvenescence has cumulatively raised roughly $295M+ across multiple private rounds, most recently a $76M Series B-1 led by Abu Dhabi-based M42 in May 2025, and acquired AI-drug-discovery company Ro5 Inc. in June 2025. The company is incorporated in the Isle of Man, operates primarily from the UK with an EU data controller entity in Dublin, and is expanding into the UAE through new research offices at Masdar City, Abu Dhabi, alongside a partnership providing access to the Emirati Genome Project's 800,000+ whole genomes. Leadership includes CEO Dr. Richard Marshall CBE (appointed January 2023), CTO Eileen Jennings-Brown (appointed February 2026), CSO Gill Dines, and co-founders Jim Mellon, Dr. Greg Bailey, and Dr. Declan Doogan.

Juvenescence is pre-revenue and does not yet have commercialized products or public pricing. Its business model is built on eventual monetization through licensing, co-development partnerships, or acquisition by large pharmaceutical companies, as exemplified by portfolio company Relation Therapeutics' Novartis and GSK deals. Customer relationships today are essentially institutional: M42 functions as both lead investor and strategic partner, the Buck Institute as a research collaborator, Masdar City as an infrastructure host, and large pharma as the prospective future acquirer or licensee of pipeline assets. Marketing and commercial development are conducted through scientific conferences, industry forums (including The Longevity Forum in London), investor relations communications, and selective media engagement rather than traditional sales channels.

Short descriptiontext

Juvenescence is a clinical-stage, AI-enabled biotechnology company developing medicines that target core mechanisms of aging to treat and prevent age-related diseases, using its proprietary JuvAI platform and a portfolio of therapeutic and investment assets spanning cognition, cardio-metabolism, immunity, and cellular repair.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersDublin, Ireland
HQ citystring
Dublin
HQ countrystring
Ireland
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, longevity therapeutics, clinical-stage biotech, aging biology research, pharmaceutical development
Industry2 codes
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
Product category
Longevity Therapeutics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Therapeutic Development and Commercialization
TypeOne Time License
Description

Pre-revenue clinical stage company developing medicines targeting core aging mechanisms. Revenue will be generated through eventual commercialization of therapeutics upon regulatory approval, with potential for licensing, co-development partnerships, or acquisition by larger pharmaceutical companies.

juvlabs.com
2Strategic Partnerships and Licensing
TypeLicensing Royalties
Description

The company generates value through strategic partnerships with pharmaceutical companies (evidenced by portfolio company Relation Therapeutics' $1.7B Novartis collaboration and $300M GSK collaborations) and may pursue similar licensing deals for its own pipeline assets upon clinical validation.

juvlabs.com
3Portfolio Company Returns
TypeSubscription Recurring
Description

Investments in portfolio companies (Serina Therapeutics, Relation Therapeutics, LyGenesis, Morphoceuticals, Component Health, Chrysea, PerformAge, MDI Therapeutics, BYOMass, Souvien Therapeutics) may generate returns through equity appreciation, IPOs, or acquisitions of portfolio companies.

juvlabs.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1JuvAI
Description

Fully integrated AI system spanning JuvAI Biology (LLM-enabled biomedical knowledge graph), JuvAI Chemistry (AI/ML platform for molecular design and optimization), and JuvAI Clinic (ML tools for adaptive clinical trials and precision patient selection).

juvlabs.com
+2 more records
Core offering1 text field

Juvenescence is a clinical-stage biotech developing first-in-class therapeutics that target core mechanisms of aging to treat and prevent age-related diseases. Its pipeline includes PAI-1 Inhibitor (MDI-2517), GDF-15 monoclonal antibody, CD38 Inhibitor (NTX-748), Ketone Rx, and Plasmalogen candidates across cognition, cardio-metabolism, immunity, and cellular repair areas. Drug discovery is powered by the proprietary JuvAI platform combining a biomedical knowledge graph with AI/ML for molecular design and adaptive clinical trials.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • PAI-1 inhibitor (MDI-2517) demonstrated safety, tolerability, and suitability for once-daily dosing in Phase 1 trials, advancing to Phase 2 for chronic kidney disease and fibrotic lung disease
+3 more records
Product overview1 text field

Juvenescence is a clinical-stage AI-enabled biotech developing medicines to extend healthy lifespan by targeting core aging mechanisms. The company's core offering is the JuvAI integrated AI platform (JuvAI Biology, JuvAI Chemistry, JuvAI Clinic) powering a pipeline of five core medicines including PAI-1 Inhibitor (MDI-2517), GDF-15 mAb, CD38 Inhibitor, Ketone Rx, and Plasmalogen. The portfolio spans across cognition, cardio-metabolism, immunity, and cellular repair therapeutic areas. Juvenescence operates a strategic portfolio model with investments in platform technologies and companies including Serina Therapeutics (drug delivery), Relation Therapeutics (AI biology), LyGenesis (organ regeneration), Morphoceuticals (bioelectrome), Chrysea (nutritional supplements via Sprevive), and PerformAge (digital health). The company was founded by Jim Mellon, Dr. Greg Bailey, and Dr. Declan Doogan, with leadership by Dr. Richard Marshall CBE, and maintains operations in the UK, UAE (Masdar City), and Ramsey, Isle of Man.

Product and service3 records
1JuvAI Platform
CategoryAI Drug Discovery Platform
Description

Integrated AI system for drug discovery spanning target selection to clinical trials, comprising JuvAI Biology, JuvAI Chemistry, and JuvAI Clinic modules. Used internally by Juvenescence to advance its aging-targeting therapeutic pipeline.

2PAI-1 Inhibitor (MDI-2517)
CategoryAging Therapeutics - Pipeline Drug
Description

First-in-class PAI-1 inhibitor drug candidate targeting fundamental aging mechanisms. Demonstrated safety and tolerability in Phase 1 trials for once-daily dosing and advancing to Phase 2 for chronic kidney disease and fibrotic lung disease.

3GDF-15 mAb
Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
1Masdar City
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-16
Description

Abu Dhabi's premier life sciences and biotechnology hub providing world-class infrastructure, proximity to leading regional research institutions, government-backed initiatives from Abu Dhabi Department of Health and Abu Dhabi Investment Office, and access to growing biotech community. Juvenescence establishing Advanced AI Drug Discovery Laboratory at this location.

juvlabs.com
2Emirati Genome Project
Strategic tierCoreTypeOthers
Description

UAE's national genomic initiative providing access to 800,000+ whole genomes dataset. Enables Juvenescence to leverage unprecedented genomic and health data for precision medicine development and clinical trial acceleration through M42 partnership.

juvlabs.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Leading research institution focused solely on aging research. Ongoing collaboration with Dr. Eric Verdin's lab on CD38 inhibitor program (NTX-748) for cognitive decline in aging. Dr. Verdin presented data showing CD38 inhibition may enhance cognitive performance by modulating NAD metabolism.

Strategic tierCoreTypeTechnology or Integration
Description

Acquired AI drug discovery company in June 2025. Enhanced Juvenescence's AI/ML drug discovery capabilities with proprietary Biomedical Knowledge Graph (85M+ nodes, 400M+ relationships) and AI Chemistry Platform. Critical component of M42 strategic partnership for AI-enabled drug discovery.

Strategic tierPortfolioTypeOthers
Description

Portfolio company with foundational platforms based on proprietary Poly-oxazoline (POZ) technology for delivering small molecules and biologics.

Strategic tierPortfolioTypeOthers
Description

Portfolio company with platform technology discovering relationships at the heart of biology. Lab-in-the-Loop approach combining human genetics, single cell multi-omics, functional assays and ML. Announced $1.7B strategic collaboration with Novartis for atopic diseases and $300M+ collaborations with GSK.

Strategic tierPortfolioTypeOthers
Description

Portfolio company utilizing lymph nodes as in-vivo bioreactors to grow functioning ectopic organs. Lead cell therapy in Phase 2a for End-Stage Liver Disease with dose escalation approved.

Strategic tierPortfolioTypeOthers
Description

Portfolio company manipulating bioelectrome to induce regeneration and treat disease. Collaboration with Prof Michael Levin and Prof David Kaplan.

Strategic tierPortfolioTypeOthers
Description

Portfolio company and synthetic biology pioneer developing healthy nutritional interventions. Launched Sprevive - pure spermidine formulation using patented precision fermentation. Presented study results at Gordon Research Conference showing associations between higher spermidine intake and lower cardiovascular risk.

Strategic tierPortfolioTypeOthers
Description

Portfolio company with proprietary digital health platform.

Strategic tierPortfolioTypeOthers
Description

Portfolio company developing novel serpin-based therapies for fibrotic disease.

12Napa Therapeutics
Strategic tierPortfolioTypeStrategic or Co-development Partner
Description

Joint venture with Buck Institute and Insilico Medicine established in 2018 to advance therapeutics targeting aging mechanisms.

juvlabs.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AI-driven drug discovery company developing therapeutics for aging and age-related diseases. Directly comparable as both leverage generative AI and omics-based target identification to advance aging biology into the clinic, and Insilico is a co-founder of Juvenescence's Napa Therapeutics joint venture.

TypeDirect peer
Description

Well-capitalized ($3B) biotech pursuing cellular rejuvenation to reverse aging and age-related disease. Direct competitor for talent, partnership mindshare, and clinical proof-of-concept in the core aging-mechanism thesis Juvenescence is built on.

TypeDirect peer
Description

Alphabet-backed longevity biotech targeting fundamental mechanisms of aging and age-related disease. Comparable as a deep-pocketed, long-horizon R&D organization pursuing similar biology with substantially greater capital.

TypeDirect peer
Description

Clinical-stage biotech developing senolytic medicines to treat age-related diseases. Direct peer in modality (small molecules targeting aging biology) and indication space (ocular, musculoskeletal, pulmonary).

TypeDirect peer
Description

AI-enabled biotech discovering and developing therapeutics that target molecular drivers of aging. Highly comparable as a clinical-stage, AI-native longevity company targeting core aging pathways with a similar partnership-driven business model.

TypeEmerging player
Description

Early-stage company developing epigenetic reprogramming therapies to restore youthful function in aged cells. Comparable in its focus on core aging mechanisms but earlier-stage and focused on cellular reprogramming rather than small-molecule/mAb discovery.

TypeEmerging player
Description

Developer of FDA-acknowledged longevity drugs (veterinary first). Comparable as a longevity therapeutics company pursuing regulatory pathways for aging intervention, but operates in animal health rather than human therapeutics.

TypeBroad incumbent
Description

Larger AI-driven drug discovery company with a broader therapeutic-area focus. Comparable on the AI platform layer (Juvenescence's new CTO came from Exscientia) but Exscientia is a public, larger-scale pharma partner rather than a focused aging specialist.

TypeBroad incumbent
Description

Publicly listed AI-enabled biotech combining high-throughput biology with machine learning for drug discovery. Comparable as an AI-native drug discovery peer but operates across many therapeutic areas with a much larger capital base.

TypeBroad incumbent
Description

Public computational chemistry and biology platform serving pharma R&D. Comparable in providing physics-based and ML drug discovery capabilities that overlap with Juvenescence's JuvAI Chemistry stack, but operates as a broad software-and-services platform rather than an aging-focused therapeutic developer.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature10 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries11 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment14 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Juvenescence

Longevity Therapeuticsjuvlabs.com

Juvenescence is a clinical-stage, AI-enabled biotechnology company developing medicines that target core mechanisms of aging to treat and prevent age-related diseases, using its proprietary JuvAI platform and a portfolio of therapeutic and investment assets spanning cognition, cardio-metabolism, immunity, and cellular repair.

What Juvenescence does

Juvenescence is a clinical-stage AI-enabled biotechnology company developing medicines that target core mechanisms of aging to treat and prevent age-related diseases rather than individual disease symptoms. Its pipeline spans five core therapeutic candidates: a PAI-1 inhibitor (MDI-2517) advancing to Phase 2 in chronic kidney disease and fibrotic lung disease, a CD38 inhibitor (NTX-748) targeting NAD metabolism and cognitive aging, a GDF-15 monoclonal antibody for cardio-metabolic conditions, plus Ketone Rx and Plasmalogen candidates. Underpinning the pipeline is the proprietary JuvAI platform, which combines JuvAI Biology (an LLM-enabled biomedical knowledge graph with 85 million nodes and 400 million relationships), JuvAI Chemistry (point-cloud ML and a 3D variational GAN for molecular design), and JuvAI Clinic (adaptive clinical trial optimization). Nine granted patents protect core platform components.

The company operates a dual model combining internal pipeline development with a strategic portfolio of minority investments in adjacent platform companies, including Relation Therapeutics ($1.7B Novartis collaboration), LyGenesis (Phase 2a liver cell therapy), Morphoceuticals, Chrysea (Sprevive spermidine supplement), MDI Therapeutics, Serina Therapeutics, Napa Therapeutics (joint venture with Buck Institute and Insilico Medicine), and others. Juvenescence has cumulatively raised roughly $295M+ across multiple private rounds, most recently a $76M Series B-1 led by Abu Dhabi-based M42 in May 2025, and acquired AI-drug-discovery company Ro5 Inc. in June 2025. The company is incorporated in the Isle of Man, operates primarily from the UK with an EU data controller entity in Dublin, and is expanding into the UAE through new research offices at Masdar City, Abu Dhabi, alongside a partnership providing access to the Emirati Genome Project's 800,000+ whole genomes. Leadership includes CEO Dr. Richard Marshall CBE (appointed January 2023), CTO Eileen Jennings-Brown (appointed February 2026), CSO Gill Dines, and co-founders Jim Mellon, Dr. Greg Bailey, and Dr. Declan Doogan.

Juvenescence is pre-revenue and does not yet have commercialized products or public pricing. Its business model is built on eventual monetization through licensing, co-development partnerships, or acquisition by large pharmaceutical companies, as exemplified by portfolio company Relation Therapeutics' Novartis and GSK deals. Customer relationships today are essentially institutional: M42 functions as both lead investor and strategic partner, the Buck Institute as a research collaborator, Masdar City as an infrastructure host, and large pharma as the prospective future acquirer or licensee of pipeline assets. Marketing and commercial development are conducted through scientific conferences, industry forums (including The Longevity Forum in London), investor relations communications, and selective media engagement rather than traditional sales channels.

Juvenescence firmographics

Firmographics
Name
Juvenescence
Legal name
Juvenescence Limited
Website
https://juvlabs.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Juvenescence is a clinical-stage, AI-enabled biotechnology company developing medicines that target core mechanisms of aging to treat and prevent age-related diseases, using its proprietary JuvAI platform and a portfolio of therapeutic and investment assets spanning cognition, cardio-metabolism, immunity, and cellular repair.
Ownership category
akta.pro rank

Juvenescence industry classification

Industry
Product category
Longevity Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
akta.pro industry
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • AI drug discovery
  • Longevity therapeutics
  • Clinical-stage biotech
  • Aging biology research
  • Pharmaceutical development

Where Juvenescence is headquartered

Location

Headquarters

HQ city
Dublin
HQ country
Ireland
HQ region
Europe

Offices4 records

Markets served

Juvenescence business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Therapeutic Development and Commercialization: Pre-revenue clinical stage company developing medicines targeting core aging mechanisms. Revenue will be generated through eventual commercialization of therapeutics upon regulatory approval, with potential for licensing, co-development partnerships, or acquisition by larger pharmaceutical companies.
  2. Strategic Partnerships and Licensing: The company generates value through strategic partnerships with pharmaceutical companies (evidenced by portfolio company Relation Therapeutics' $1.7B Novartis collaboration and $300M GSK collaborations) and may pursue similar licensing deals for its own pipeline assets upon clinical validation.
  3. Portfolio Company Returns: Investments in portfolio companies (Serina Therapeutics, Relation Therapeutics, LyGenesis, Morphoceuticals, Component Health, Chrysea, PerformAge, MDI Therapeutics, BYOMass, Souvien Therapeutics) may generate returns through equity appreciation, IPOs, or acquisitions of portfolio companies.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Juvenescence product offering

Product offering

Core offering

Juvenescence is a clinical-stage biotech developing first-in-class therapeutics that target core mechanisms of aging to treat and prevent age-related diseases. Its pipeline includes PAI-1 Inhibitor (MDI-2517), GDF-15 monoclonal antibody, CD38 Inhibitor (NTX-748), Ketone Rx, and Plasmalogen candidates across cognition, cardio-metabolism, immunity, and cellular repair areas. Drug discovery is powered by the proprietary JuvAI platform combining a biomedical knowledge graph with AI/ML for molecular design and adaptive clinical trials.

Product overview

Juvenescence is a clinical-stage AI-enabled biotech developing medicines to extend healthy lifespan by targeting core aging mechanisms. The company's core offering is the JuvAI integrated AI platform (JuvAI Biology, JuvAI Chemistry, JuvAI Clinic) powering a pipeline of five core medicines including PAI-1 Inhibitor (MDI-2517), GDF-15 mAb, CD38 Inhibitor, Ketone Rx, and Plasmalogen. The portfolio spans across cognition, cardio-metabolism, immunity, and cellular repair therapeutic areas. Juvenescence operates a strategic portfolio model with investments in platform technologies and companies including Serina Therapeutics (drug delivery), Relation Therapeutics (AI biology), LyGenesis (organ regeneration), Morphoceuticals (bioelectrome), Chrysea (nutritional supplements via Sprevive), and PerformAge (digital health). The company was founded by Jim Mellon, Dr. Greg Bailey, and Dr. Declan Doogan, with leadership by Dr. Richard Marshall CBE, and maintains operations in the UK, UAE (Masdar City), and Ramsey, Isle of Man.

Differentiator

Problem solved

Functional benefit

Brands

  • JuvAI: Fully integrated AI system spanning JuvAI Biology (LLM-enabled biomedical knowledge graph), JuvAI Chemistry (AI/ML platform for molecular design and optimization), and JuvAI Clinic (ML tools for adaptive clinical trials and precision patient selection).
  • JuvTherapeutics
  • Sprevive

Products and services

  • JuvAI Platform Integrated AI system for drug discovery spanning target selection to clinical trials, comprising JuvAI Biology, JuvAI Chemistry, and JuvAI Clinic modules. Used internally by Juvenescence to advance its aging-targeting therapeutic pipeline.
  • PAI-1 Inhibitor (MDI-2517) First-in-class PAI-1 inhibitor drug candidate targeting fundamental aging mechanisms. Demonstrated safety and tolerability in Phase 1 trials for once-daily dosing and advancing to Phase 2 for chronic kidney disease and fibrotic lung disease.
  • GDF-15 mAb

Quantifiable outcome

  • PAI-1 inhibitor (MDI-2517) demonstrated safety, tolerability, and suitability for once-daily dosing in Phase 1 trials, advancing to Phase 2 for chronic kidney disease and fibrotic lung disease
  • +3 more outcomes

Companies that use Juvenescence

Customer profile

Segments3 records

Ideal customer profiles3 records

Juvenescence technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature10 records

Juvenescence partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered core and portfolio.

  • Masdar CitycoreStrategic or Co-development Partner · 16 February 2026Abu Dhabi's premier life sciences and biotechnology hub providing world-class infrastructure, proximity to leading regional research institutions, government-backed initiatives from Abu Dhabi Department of Health and Abu Dhabi Investment Office, and access to growing biotech community. Juvenescence establishing Advanced AI Drug Discovery Laboratory at this location.
  • Emirati Genome ProjectcoreOthersUAE's national genomic initiative providing access to 800,000+ whole genomes dataset. Enables Juvenescence to leverage unprecedented genomic and health data for precision medicine development and clinical trial acceleration through M42 partnership.
  • Buck Institute for Research on AgingcoreStrategic or Co-development PartnerLeading research institution focused solely on aging research. Ongoing collaboration with Dr. Eric Verdin's lab on CD38 inhibitor program (NTX-748) for cognitive decline in aging. Dr. Verdin presented data showing CD38 inhibition may enhance cognitive performance by modulating NAD metabolism.
  • Ro5 Inc.coreTechnology or IntegrationAcquired AI drug discovery company in June 2025. Enhanced Juvenescence's AI/ML drug discovery capabilities with proprietary Biomedical Knowledge Graph (85M+ nodes, 400M+ relationships) and AI Chemistry Platform. Critical component of M42 strategic partnership for AI-enabled drug discovery.
  • Serina TherapeuticsportfolioOthersPortfolio company with foundational platforms based on proprietary Poly-oxazoline (POZ) technology for delivering small molecules and biologics.
  • Relation TherapeuticsportfolioOthersPortfolio company with platform technology discovering relationships at the heart of biology. Lab-in-the-Loop approach combining human genetics, single cell multi-omics, functional assays and ML. Announced $1.7B strategic collaboration with Novartis for atopic diseases and $300M+ collaborations with GSK.
  • LyGenesisportfolioOthersPortfolio company utilizing lymph nodes as in-vivo bioreactors to grow functioning ectopic organs. Lead cell therapy in Phase 2a for End-Stage Liver Disease with dose escalation approved.
  • MorphoceuticalsportfolioOthersPortfolio company manipulating bioelectrome to induce regeneration and treat disease. Collaboration with Prof Michael Levin and Prof David Kaplan.
  • ChryseaportfolioOthersPortfolio company and synthetic biology pioneer developing healthy nutritional interventions. Launched Sprevive - pure spermidine formulation using patented precision fermentation. Presented study results at Gordon Research Conference showing associations between higher spermidine intake and lower cardiovascular risk.
  • PerformAgeportfolioOthersPortfolio company with proprietary digital health platform.
  • MDI TherapeuticsportfolioOthersPortfolio company developing novel serpin-based therapies for fibrotic disease.
  • Napa TherapeuticsportfolioStrategic or Co-development PartnerJoint venture with Buck Institute and Insilico Medicine established in 2018 to advance therapeutics targeting aging mechanisms.

Scale indicators9 records

Recent moves8 records

Expansion highlights6 records

Juvenescence competitors and assessment

Company assessment

Direct peers

  • Insilico Medicine: AI-driven drug discovery company developing therapeutics for aging and age-related diseases. Directly comparable as both leverage generative AI and omics-based target identification to advance aging biology into the clinic, and Insilico is a co-founder of Juvenescence's Napa Therapeutics joint venture.
  • Altos Labs: Well-capitalized ($3B) biotech pursuing cellular rejuvenation to reverse aging and age-related disease. Direct competitor for talent, partnership mindshare, and clinical proof-of-concept in the core aging-mechanism thesis Juvenescence is built on.
  • Calico Life Sciences: Alphabet-backed longevity biotech targeting fundamental mechanisms of aging and age-related disease. Comparable as a deep-pocketed, long-horizon R&D organization pursuing similar biology with substantially greater capital.
  • Unity Biotechnology: Clinical-stage biotech developing senolytic medicines to treat age-related diseases. Direct peer in modality (small molecules targeting aging biology) and indication space (ocular, musculoskeletal, pulmonary).
  • BioAge Labs: AI-enabled biotech discovering and developing therapeutics that target molecular drivers of aging. Highly comparable as a clinical-stage, AI-native longevity company targeting core aging pathways with a similar partnership-driven business model.

Emerging players

  • NewLimit: Early-stage company developing epigenetic reprogramming therapies to restore youthful function in aged cells. Comparable in its focus on core aging mechanisms but earlier-stage and focused on cellular reprogramming rather than small-molecule/mAb discovery.
  • Loyal for Dogs: Developer of FDA-acknowledged longevity drugs (veterinary first). Comparable as a longevity therapeutics company pursuing regulatory pathways for aging intervention, but operates in animal health rather than human therapeutics.

Broad incumbents

  • Exscientia: Larger AI-driven drug discovery company with a broader therapeutic-area focus. Comparable on the AI platform layer (Juvenescence's new CTO came from Exscientia) but Exscientia is a public, larger-scale pharma partner rather than a focused aging specialist.
  • Recursion Pharmaceuticals: Publicly listed AI-enabled biotech combining high-throughput biology with machine learning for drug discovery. Comparable as an AI-native drug discovery peer but operates across many therapeutic areas with a much larger capital base.
  • Schrödinger, Inc. Public computational chemistry and biology platform serving pharma R&D. Comparable in providing physics-based and ML drug discovery capabilities that overlap with Juvenescence's JuvAI Chemistry stack, but operates as a broad software-and-services platform rather than an aging-focused therapeutic developer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Juvenescence social profiles

Digital presence

Juvenescence financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Juvenescence leadership team

Management profile

Number of profiles

Profiles8 records

Juvenescence subsidiaries and ownership

Company hierarchy

Subsidiaries11 records

Juvenescence funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Juvenescence M&A and investment

M&A and investment

M&A2 records

Investments14 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Juvenescence

What does Juvenescence do?

Juvenescence is a clinical-stage biotech developing first-in-class therapeutics that target core mechanisms of aging to treat and prevent age-related diseases. Its pipeline includes PAI-1 Inhibitor (MDI-2517), GDF-15 monoclonal antibody, CD38 Inhibitor (NTX-748), Ketone Rx, and Plasmalogen candidates across cognition, cardio-metabolism, immunity, and cellular repair areas. Drug discovery is powered by the proprietary JuvAI platform combining a biomedical knowledge graph with AI/ML for molecular design and adaptive clinical trials.

Is Juvenescence a public or private company?

Juvenescence is a private company. It is classified as venture growth investor backed and is currently operating.

When was Juvenescence founded?

Juvenescence was founded in 2016. It employs 11 to 50 people.

Where is Juvenescence based?

Juvenescence is headquartered in Dublin, Ireland, in the Europe region.

How does Juvenescence make money?

Three revenue lines are on record. Therapeutic Development and Commercialization is the primary driver. The others are strategic Partnerships and Licensing and portfolio Company Returns.

Who are Juvenescence's main competitors?

Direct peers on record are Insilico Medicine, Altos Labs, Calico Life Sciences, Unity Biotechnology and BioAge Labs. Emerging players are NewLimit and Loyal for Dogs. Broad incumbents are Exscientia, Recursion Pharmaceuticals and Schrödinger, Inc..

Does Juvenescence have an API?

No public API is recorded for Juvenescence.

What industry is Juvenescence in?

Juvenescence's product category is Longevity Therapeutics. Its primary akta.pro industry code is HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation), with a secondary code of HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution). Its NAICS code is 541714.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Longevity.TechnologyJuvenescence advances aging drug to Phase 2 trialJuvenescence, an AI-enabled biotech company focused on longevity, has successfully completed Phase 1 trials for its first-in-class PAI-1 inhibitor MDI-2517, demonstrating the drug is safe, well-tolerated, and suitable for once-daily dosing. The company is now advancing the drug to Phase 2 trials, targeting age-related conditions including chronic kidney disease and fibrotic lung disease. The Phase 1 results support Juvenescence's strategy of targeting fundamental aging mechanisms rather than treating disease symptoms, with broader pipeline programs for cardiovascular disease, muscle wasting, and rheumatoid arthritis scheduled to enter clinical testing within 12 months.GlobeNewswireJuvenescence appoints Eileen Jennings-Brown as Chief Technology Officer and strengthens presence in UAE with new partnership and facilities with Masdar CityJuvenescence Limited announced the appointment of Eileen Jennings-Brown as Chief Technology Officer and expanded its operations in the UAE by establishing new research offices at Masdar City, Abu Dhabi. The company's strategic move aims to support drug discovery and clinical research leveraging AI and genomic data in the UAE's biotech ecosystem.BioSpaceJuvenescence appoints Eileen Jennings-Brown as Chief Technology Officer and strengthens presence in UAE with new partnership and facilities with Masdar CityJuvenescence Limited, a clinical-stage AI-enabled biotech company, appointed Eileen Jennings-Brown as Chief Technology Officer and announced expansion of its operations in the UAE through new research offices at Masdar City, Abu Dhabi. The expansion builds on Juvenescence's strategic investment from M42 and includes plans to establish an Advanced AI Drug Discovery Laboratory leveraging the Emirati Genome Project's dataset of over 800,000 whole genomes. The move supports the UAE's ambition to establish a global hub for biotechnology and life sciences.SalesTech StarJuvenescence Appoints Eileen Jennings-Brown as Chief Technology Officer and Strengthens Presence in UAE With New Partnership and Facilities With Masdar CityJuvenescence, a clinical-stage AI-enabled longevity biotech, has appointed Eileen Jennings-Brown as Chief Technology Officer and announced a major expansion into the UAE through new research offices at Masdar City in Abu Dhabi. Jennings-Brown brings over 25 years of technology leadership experience, including prior roles at Exscientia and the Wellcome Trust, and will drive the company's global AI and data strategy. This expansion builds on a strategic investment from M42 announced in April 2025 and aligns with the UAE's ambition to establish a global biotechnology hub, including access to the Emirati Genome Project's 800,000+ whole genomes dataset.Longevity.TechnologyJuvenescence expands into Abu DhabiLongevity biotech firm Juvenescence has announced an expansion into Abu Dhabi's Masdar City, establishing operations as part of a broader collaboration with UAE partners that includes access to large-scale genomic and health data. The move pairs the company's JuvAI platform with the UAE's population-scale genomics infrastructure, including the Emirati Genome Project's 800,000+ whole genomes, and positions Juvenescence within a healthcare system oriented toward prevention and precision medicine. The company also confirmed the appointment of Eileen Jennings-Brown as Chief Technology Officer, bringing experience in AI-enabled drug discovery to support its geographic and computational expansion.openPR.comFuture Perspectives: Key Trends Shaping the Longevity BioTech Market up to 2030The longevity biotech market is projected to grow to $34.82 billion by 2030, driven by technological advancements, strategic partnerships, and increasing demand for gene-based therapies. Multiple influential companies, including Juvenescence Limited and Ro5 Inc., are actively shaping this market through acquisitions and innovations.AETOSWireJUVENESCENCE Appoints Dr Richard Marshall CBE as CEOJuvenescence appointed Dr Richard Marshall CBE as CEO, effective 16 January 2023, succeeding co-founder Dr Gregory Bailey, who remains Executive Chairman. Marshall brings over 20 years of leadership, including 15 years at GSK and a recent role at AstraZeneca. The company focuses on therapies to modify aging and increase healthy lifespan.Monaco TribuneInside the new longevity elite: the startups redefining how we ageDr. Aleks Letnikovs examines the longevity biotech sector, profiling key startups including Altos Labs (which raised $3 billion starting in 2022), Retro Biosciences ($1.2 billion backed), Unity Biotechnology (whose 2020 osteoarthritis trial failed to meet primary endpoints), and consumer-facing companies such as Juvenescence, CohBar, Tally Health, InsideTracker, and Aging.ai. The article argues that while significant capital has flowed into the sector and human trials like the TAME metformin study are yielding early insights, the gap between animal research and human applications remains a fundamental challenge, with most therapies still years from clinical practice. Demographic pressure adds urgency, as populations in Europe, the United States, and Asia are projected to have over 20% of citizens over 65 by 2030.The Pharma LetterJuvenescence raises $76 million in first-close of Series B-1 roundUK-based Juvenescence, a clinical-stage AI-enabled biotech company, has secured $76 million in the first close of its Series B-1 funding round, with M42 serving as the cornerstone investor alongside follow-on investments from existing shareholders. The funding will support the company's continued development of AI-enabled therapeutics in the longevity and aging space. This marks a significant capital infusion for the clinical-stage firm as it advances its pipeline.JuvlabsM42 Announces Strategic Investment and Partnership with Leading Biotech JuvenescenceM42 announced a strategic investment and partnership with Juvenescence to develop AI-enabled therapeutics for age-related diseases. The collaboration will accelerate Juvenescence's clinical pipeline and align with M42's AI Life Sciences Platform. The partnership aims to build a pipeline of innovative medicines targeting core aging mechanisms.